Trial to Study the Efficacy and Safety of BEJO Red Ginger in COVID-19 Patients With Mild Symptoms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

168 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-22

Study Completion Date

2022-08-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a randomized, double-blind, placebo-controlled clinical trial to investigate the safety and efficacy of BEJO Red Ginger in hospitalized adult (18 - 50 years old) COVID-19 patients with mild clinical manifestations.

Subjects will be screened during hospitalization. One hundred and sixty-eight patients with confirmed SARS-CoV-2 infection and meeting all criteria, will be recruited to receive either BEJO Red Ginger or placebo in addition to standard of care (SOC) in a 1:1 ratio.

Patients with a diagnosis of COVID-19 and, due to mild symptoms, hospitalized, will be randomized to take a sachet of syrups containing 15 ml of BEJO Red Ginger, 3 times a day: 1 sachet after breakfast, 1 sachet after lunch, and 1 sachet after dinner, as add-on to the SOC, with 2 hours of incubation of SOC. The treatment will last for 14 days or until patients to be declared as cured. The treated patients will be compared with an equal group treated with placebo and SOC. Recovery time, symptoms, and objective (inflammatory) parameters (see detailed description) will be analyzed as outcomes. The goal of this study is to evaluate the role of BEJO Red Ginger in preventing progression of COVID-19 and accelerating healing process in patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Controlled Clinical Trial to Evaluate The Efficacy and Safety of Healthtone as Prophylaxis for COVID-19

NCT05308615

COVID-19

COMPLETED NA

Efficacy and Immunomodulator Impact of Herbal Combination on COVID-19 Patients Recovery

NCT06636760

COVID 19

COMPLETED NA

Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)

NCT04790240

Covid19 Virus Infection

RECRUITING PHASE1/PHASE2

RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19

NCT04939415

Covid19

COMPLETED PHASE1

Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19

NCT05019326

Covid19

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

patient will be randomized 1:1 to placebo with SOC and BEJO Red Ginger with standard of care (SOC).

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group (BEJO Red Ginger Extract)

84 patients, dosage: BEJO Red Ginger Extract orally administrated 3 times a day each 15 mL plus the standard COVID-19 treatment as per hospital guideline with 2 hours interval time. (Time frame: from randomization to day 14 or until hospital discharge)

Group Type EXPERIMENTAL

BEJO Red Ginger Extract

Intervention Type DIETARY_SUPPLEMENT

BEJO Red Ginger Extract ingredients:

* Zingiber officinale var. rubrum (Rhizome extract) 80 mg
* Foeniculi vulgare Fructus (Fennel) 25 mg
* Menthae arvensis Folium (Mint) 5 mg
* Piper retrofractum Fructus (Javanese long pepper) 12.5 mg
* Honey 7500 mg

Control Group (Placebo)

84 patients, dosage: Placebo orally administrated 3 times a day each 15 mL plus the standard COVID-19 treatment as per hospital guideline with 2 hours interval time. (Time frame: from randomization to day 14 or until hospital discharge)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo composition: Substance without active ingredient

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BEJO Red Ginger Extract

BEJO Red Ginger Extract ingredients:

* Zingiber officinale var. rubrum (Rhizome extract) 80 mg
* Foeniculi vulgare Fructus (Fennel) 25 mg
* Menthae arvensis Folium (Mint) 5 mg
* Piper retrofractum Fructus (Javanese long pepper) 12.5 mg
* Honey 7500 mg

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo composition: Substance without active ingredient

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 50 years, both sexes.
* Newly diagnosed adult patients with positive SARS-COV-2 by Real Time-PCR, using an appropriate sample such as nasopharyngeal, oropharyngeal, or nasal swab (within 3 days prior to study enrolment).
* Patients diagnosed with mild clinical manifestations, according to the Management of COVID-19 patients issued by The Indonesian Society of Respirology (Kepmenkes HK.0107/MENKES/5671/2021). Mild symptoms including fever, cough, shortness of breath, myalgia, sore throat, anosmia, diarrhea, nauseous and other symptoms.
* Hospitalized patients.
* Subject must have provided written informed consent which includes signing the institutional review board approved consent form prior to participating.

Exclusion Criteria

* Asymptomatic COVID-19 patients
* Presence of any of the following abnormal laboratory values:

* Elevation in serum glutamic oxaloacetic transaminase (SGOT) and/ or serum glutamic pyruvic transaminase (SGPT) of greater than 5 times the upper limit of normal (SGOT normal value 34 - 45 UI; SGPT normal value 31 - 35 UI)
* Elevation in urea and creatinine blood levels of greater than the upper limit of normal (Urea normal value 10 - 44 mg/dL; creatinine normal value 0.4 - 1.4 mg/dL)
* Patients with severe pneumonia.
* Patients with serious co-morbidity, including: coronary heart diseases, congestive heart failure, arrhythmia, liver diseases, hypertension, diabetes mellitus (DM) type 1 and 2, glucocorticoid-induced DM, geriatric syndromes, autoimmune diseases, severe renal impairment, myocardial infarction, chronic obstructive pulmonary diseases (including asthma, tuberculosis) , and malignancies. The medical history was determined by from the statement of prospective subjects.
* Patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), proved by an electrocardiogram (ECG) result.
* Be pregnant, confirmed with a negative pregnancy test.
* Lactating and breast feeding.
* Has consumed, or consuming herbal medicines or supplements other than SOC for COVID-10 in RSDC Wisma Atlet.
* Patient who has allergies to the test product.
* Active participation in other drug clinical trials.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No